Danaher Corporation's Life Sciences segment
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Business Segment
|
| gptkbp:acquisition |
gptkb:GE_Biopharma
|
| gptkbp:collaboratesWith |
Research Institutions
|
| gptkbp:contributedTo |
Scientific Research
Clinical Diagnostics Healthcare_Solutions |
| gptkbp:develops |
Innovative_Technologies
|
| gptkbp:employs |
Thousands of employees
|
| gptkbp:focusesOn |
Life_Sciences
|
| gptkbp:hasPart |
Genomics
Laboratory Automation Bioprocessing Solutions Cell Analysis |
| gptkbp:hasResidence |
$7 billion (2022)
|
| gptkbp:hasSubsidiary |
gptkb:Beckman_Coulter
gptkb:Pall_Corporation gptkb:Molecular_Devices gptkb:Cytiva |
| gptkbp:headquarteredIn |
gptkb:Washington,_D.C.
|
| https://www.w3.org/2000/01/rdf-schema#label |
Danaher Corporation's Life Sciences segment
|
| gptkbp:isActiveIn |
Emerging Markets
Global_Markets |
| gptkbp:isInvolvedIn |
Clinical Trials
Market Research Quality Control Product Development Regulatory Compliance |
| gptkbp:isKnownFor |
Customer Support
Innovative_Research High-Quality_Products |
| gptkbp:isLinkedTo |
Technological Innovations
Scientific Discoveries Healthcare Advancements Patient Care Improvements |
| gptkbp:isPartOf |
Danaher_Business_System
|
| gptkbp:isRecognizedFor |
Innovation Awards
Sustainability Initiatives Industry Leadership |
| gptkbp:isRegulatedBy |
gptkb:FDA
EMA |
| gptkbp:isSupportedBy |
Acquisitions
Strategic Partnerships Strong R&D |
| gptkbp:offers |
Protein Analysis Tools
Cell_Culture_Products Genomics_Solutions Flow_Cytometry_Products |
| gptkbp:operatesIn |
Biotechnology
Pharmaceuticals Diagnostics |
| gptkbp:partOf |
gptkb:Danaher_Corporation
|
| gptkbp:provides |
Software Solutions
Consumables Laboratory Instruments Reagents |